Kornimate/medical-research-clean huggingface dataset:
biomedical research informatics centre for cardiovascular sciences (the briccs study)

Conditions: Cardiovascular Diseases; Cardiovascular Risk Factor

Summary: this project will examine the diagnosis and prognosis of patients with cardiovascular disease in hospital in- and outpatients and compare their characteristics with normal controls from the community. the cardiovascular diseases studied include coronary artery disease, heart failure, heart attacks, valve disease, cardiac surgery, dysrhythmias, aneurysms, embolism, strokes, peripheral vascular disease and hypertension. current methods for diagnosis and predicting outcome in patients are limited and may lack accuracy. this study will collect clinical details, and blood and urine samples from patients for analysis of proteins, chemicals and genetic biomarkers which will enable an examination of the pathological mechanisms involved in cardiovascular disease. the data will also be used to improve diagnosis and also improve prediction of outcome in patients (future clinical events such as death, further hospitalisation with cardiovascular disease and the effects of any therapy given to the patients). in this way, we can develop accurate ways of assessing a patient's condition and how it could be effectively managed. the study will last for 20 years.


Eligibility criteria:
inclusion criteria: * all outpatients and inpatients with cardiovascular disease, of either gender * aged 18-90 years old * examples of conditions include: coronary artery disease, heart failure, heart attacks (myocardial infarction), valve disease, cardiac surgery, dysrhythmias (including atrial fibrillation), aneurysms, embolism, strokes, peripheral vascular disease, hypertension (and its complications, such as left ventricular hypertrophy) or those presenting with chest pain * healthy volunteers * aged 18-90 years old * from the community without cardiovascular or other diseases exclusion criteria: * any patient who is unable to give consent * any patient with non-cardiovascular comorbidity likely to cause death within 6 months * patients know to be infected with hiv, hepatitis b or any other agent posing an infection risk from unfixed material
mesalazine granules vs. placebo for the prevention of recurrence of diverticulitis

Conditions: Diverticulitis

Summary: the purpose of the study is to determine whether mesalazine granules compared to placebo is effective in prevention of recurrence of disease.

the purpose of the study is to demonstrate the superiority of mesalazine granules compared to placebo in terms of the primary efficacy variable proportion of recurrence-free patients within 48 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of left-sided uncomplicated diverticular disease confirmed by ultrasonography or computed tomography * presence of at least one diverticulum of the left colon * most recent attack of left-sided uncomplicated diverticulitis responding to antibiotics and/or dietary modification within the last 6 months * c-reactive protein (crp) \> upper limit of normal (uln) at the start of the most recent attack exclusion criteria: * complicated diverticular disease * right-sided diverticulitis * previous colonic surgery * presence of symptomatic organic disease of the gastrointestinal tract * active colorectal cancer or a history of colorectal cancer * hemorrhagic diathesis * active peptic ulcer disease, local intestinal infection * asthma if careful medical monitoring is not ensured * abnormal hepatic function or liver cirrhosis * abnormal renal function
the effect of the rubber hand illusion on sensory thresholds

Conditions: Healthy

Summary: the rubber hand illusion (rhi) causes a change in body perception and awareness as a result of the integration of simultaneously perceived visual and tactile stimulation. in the rubber hand illusion (rhi), which was first described in 1998, a realistic hand model is perceived as a part of the body and body awareness is impaired. in the rhi, the participant's real hand is positioned behind a screen so that it is out of sight; the rubber model hand is placed in the field of vision and in the appropriate position with the real hand. brush is applied simultaneously to the same parts of the real and rubber hands. he/she perceives the rubber hand as his own and the brush starts to feel as if it is being rubbed into his own hand. this method, which causes the illusion of body belonging, has been defined as the rubber hand illusion. during the rubber hand illusion, increased activity was observed in the ventral premotor cortex, infraparietal cortex and cerebellum in functional mri. it is suggested that this phenomenon occurs with the integration of interrelated visual, tactile and proprioceptive senses reaching the premotor cortex. quantitative sensory tests are standardized subjective clinical sensitivity tests that require the collaboration of the person to be examined. in the tests, calibrated stimuli are applied to capture perception and pain thresholds, thus providing information about sensory thresholds. the impairment of body perception caused by rhi contributes to the multi-faceted understanding of sensory perception, higher-level cognitive processes, brain mapping and functions. in the studies; it has been suggested that the conflict between visual and proprioceptive sensory information created during the rubber hand illusion is resolved by the attenuation of somatosensory input at the cortical level. as far as we know, tactile sensory threshold from quantitative sensory tests, two-point discrimination from cortical senses, pressure pain threshold measured by the algometer, and vibration threshold variation during and after rubber hand burning, which causes changes in body perception, have not been studied before. in this study, the relationship between the rhi phenomenon and sensory thresholds will be evaluated.


Eligibility criteria:
inclusion criteria: * healthy * 18-65 years old age exclusion criteria: * neuropathy * presence of any known neurological or psychiatric disease * inability to cooperate with the tests to be performed * amputation and nerve damage in the upper extremities * upper extremities dysfunction due to nerve damage

Keywords: sensory threshold rubber hand illusion
effects of of pursed lip breathing and coordinated breathing in adult patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: copd is the chronic lung condition characterized by the damage and enlargement of the air sacs in the lungs, leading to breathing difficulties. a blockage may develop, which traps air inside your lungs. the patient shows clinical manifestation of cough, wheezing, chest tightness, shortness of breath. this research of randomized clinical trial will check the combined effects of pursed lip breathing and coordinated breathing techniques to improve aerobic capacity and dyspnea in patients with copd by taking sample of 54 patients through convenience sampling and randomly allocating them to two groups a and b out of which a will receive pursed lip breathing with aerobic exercise for 4 times per week for 4 week and duration will be 45-60 min, b will receive coordinated breathing with aerobic exercise for 4 times per week for 4 weeks. and duration will be 45-60 min.pre and post training outcomes of aerobic capacity and dyspnea will be measured through six minute walk test and dyspnea borg scale, and saint george respiratory questionnaire. the data will be analyzed through spss 21.


Eligibility criteria:
inclusion criteria: * age range 25 -45 years(5) * adult patient diagnosed with (chronic obstructive pulmonary disease) based on clinical and diagnostic criteria. * patient willing and able to participate in an pursed lip breathing and coordinated breathing exercise program * gender both male and female exclusion criteria: * those who cognitive impairment that might affect their ability to comprehend and follow instructions * any contraindication to the use of pursed lip breathing or coordinated breathing exercise as determined by the health care provider. * individual with severe musculoskeletal limitations or other physical condition that may hinder the ability to perform exercise * individual who have experienced the recent exacerbation of copd symptoms within past three month

Keywords: aerobic capacity coordinated breathing technique pursed lip breathing technique.
reducing the burden of chronic psychotic disorders in tanzania (capacity)

Conditions: Schizophrenia; Medication Nonadherence; Schizo Affective Disorder

Summary: the proposed, three phase project will refine and test a first-ever care approach in ssa that combines lai with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (cpds). in addition to the novel focus, innovative elements include: 1.) a manualized curriculum that targets specific barriers and facilitators to medication adherence in tanzanians with cpd, 2.) targeting known, high-risk individuals with cpd (those who miss ≥20% of prescribed antipsychotic medication, and 3.) using existing injection clinic health workers to deliver the adherence promotion program. strengths include the highly generalizable methods and use of lais that are available in low-resource settings.

in this phase 3 portion, the study team will select appropriate measures, train staff and build capacity in measure implementation, and finalize the intervention for delivery by healthcare workers. finally, in a training/proof-of-concept exercise, the healthcare workers will implement the adapted cae-l in a high-risk sample of tanzanians with cpd (individuals with schizophrenia or schizoaffective disorder who have had recent medication adherence problems). taken together, the proposed project has substantial public health importance. it will provide the prerequisite materials, training and infrastructure needed for a prospective trial in reducing cpd burden and improving brain health in tanzania and other countries in sub-saharan africa. the focus of this project is on feasibility, patient acceptability, and research capacity-building. therefore a specific hypothesis is not being tested. the investigators will assess descriptive statistics and change from baseline in the primary and secondary measures using standard pre-post techniques.

Eligibility criteria:
inclusion criteria: * age 18 and older * diagnosis of schizophrenia or schizoaffective disorder * known to have medication treatment adherence problems as identified by the trq (20% or more missed medications in past week or past month) * ability to be rated on psychiatric rating scales * willingness to take long-acting injectable medication * able to provide written, informed consent to study participation exclusion criteria: * history of allergy or intolerance to haloperidol or haloperidol decanoate * individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment * medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial * physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist * immediate risk of harm to self or others * female who is currently pregnant or breastfeeding

Keywords: nonadherence schizophrenia africa schizoaffective
diaphragmatic myofascial release techinque on chest expansion and heart rate in patients having thoracic kyphosis

Conditions: Thoracic Kyphosis

Summary: the air of this rct is to evaluate the effects diaphragmatic myofascial release technique on chest expansion and heart rate in patients with thoracic kyphosis

this study focus on diaphragmatic release technique along with conventional therapy is more effective in improving chest expansion and with im-proved chest expansion, heart rate and blood pressure is also improved because tho-racic kyphosis impacts the way of heart and lung function creating stress response and increasing heart rate and blood pressure. lung capacity is also reduced in indi-viduals with thoracic kyphosis. postural alterations of thoracic spine result in im-paired chest expansion and length tension curve of diaphragm.

Eligibility criteria:
inclusion criteria: * both male and females * age 18-40 years * patients who consented to the purposes of this study and participated voluntarily. * patients with thoracic kyphosis ≥40 exclusion criteria: * participant failing to fall in this category would be excluded of the study. * vertebrobasilar insufficiency, rib fracture, rib dislocation and/or signs of serious pathology (e.g., malignancy, inflammatory disorder, infection); * history of cervical spine surgery in previous 12 months * signs of cervical radiculopathy or myelopathy; and vascular syndromes such as basilar insufficiency. * patients with diagnosed any respiratory condition. * patient diagnosed with hypertension or taking any medication
effect of breathing circuits on intraoperative body temperature

Conditions: Brain Tumor

Summary: to evaluate differences in intraoperative body temperature between heated huimid breathing circuit and conventional breathing circuit


Eligibility criteria:
inclusion criteria: * aged 18-70 years, * asa i or ii * patients scheduled for craniotomy under general anesthesia exclusion criteria: * asa iii or iv * duration of anesthesia time less than 4 hours * emergency operation

Keywords: core body temperature humidity circuit temperature
olaparib in adults with recurrent/metastatic ewing's sarcoma

Conditions: Ewing's Sarcoma

Summary: this research study is a phase ii clinical trial to test the efficacy of olaparib in adult participants with recurrent/metastatic ewing's sarcoma following failure of prior chemotherapy.

primary objectives evaluate the objective response rate of olaparib in adult patients with recurrent and/or metastatic ewing's sarcoma following failure of conventional chemotherapy. secondary objectives to evaluate the progression-free survival, overall survival, and safety of olaparib in this patient population (ie number of participants with adverse events). as an exploratory objective, the investigators will evaluate (in subjects who agree to an optional biopsy) differences in pre- and post-treatment tumor dna alterations and differences in levels of protein and rna expression related to parp inhibition. study design potential subjects who discuss and sign the informed consent form will undergo screening studies. eligible patients will administer olaparib and obtain restaging imaging studies after 6 and 12 weeks on study, and then every 8 weeks thereafter. participants will remain on study drug until disease progression, onset of unacceptable toxicities, or subject withdraws consent.

Eligibility criteria:
inclusion criteria: * histologically confirmed ewing's sarcoma * normal organ and bone marrow function * life expectancy of at least 16 weeks * not pregnant or breastfeeding * willing and able to comply with the protocol for the duration of the study * presence of measurable disease exclusion criteria: * involvement in the planning and/or conduct of ths study * previous enrollment in the present study * participation in another clinical study with an investigational product during the 21 days prior to first dose of study drug * previous exposure to any parp inhibitor * receiving systemic chemotherapy or radiotherapy within 2 weeks of beginning study treatment * receiving prohibited classes of inhibitors of cyp3a4 * persistent clinically significant toxicities caused by previous cancer therapy * known myelodysplastic syndrome or acute myeloid leukemia * symptomatic, uncontrolled brain metastases * major surgery within 14 days of starting study treatment * considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disorder or active, uncontrolled infection * unable to swallow orally administered medication or with gastrointestinal disorders likely to interfere with absorption of the study medication * known to be serologically positive for hiv and receiving antiretroviral therapy * known active hepatitis b or c * known hypersensitivity to olaparib or any of the excipients of the product * uncontrolled seizures

Keywords: recurrent metastatic
predicting myocardial infarction after abdominal surgery: clinical scores & biomarkers

Conditions: Myocardial Infarction

Summary: all patients undergoing non-cardiac surgery who met the inclusion criteria underwent a preoperative evaluation using specific assessment tools. following surgery, patients were closely monitored in the intermediate care unit for the first 24 hours for the development of acute myocardial infarction (ami). ami was diagnosed based on the presence of chest pain, elevated cardiac biomarkers, and specific electrocardiogram (ecg) and echocardiogram findings.


Eligibility criteria:
inclusion criteria: * patients older than 45, * patients of asa-ps grade ii-iv, * patients who prepared for non-cardiac surgeries of sss of ii-iv, * patients free of exclusion criteria, * patients signed the written consent for the study precipitation. exclusion criteria: * patients of asa-ps grade i or v, * patients younger than 60 years, * patients planned to undergo surgeries of sss \>iv, * patients were severely frail with cfs\>6, * patients had abnormal preoperative electrocardiography (ecg), * patients had a history of previous major cardiac or cerebrovascular events, * patient had disturbed cognitive function, coagulopathy, severe anemia with hemoglobin concentration (hbc) \< 7 gm/dl.
schizophrenia and the gut microbiome

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: in a sample of 20 inpatients with a dsm-iv-tr/dsm 5 diagnosis of schizophrenia or schizoaffective disorder, investigators propose to conduct a prospective, 2 week observational trial to collect gastrointestinal stool samples in order to characterize the microbiota in people with schizophrenia and examine its variability over time. participants may elect to participate for an additional two weeks, during which they will receive the prebiotic, oligofructose-enriched inulin (fos), in order to examine its effects on the relative preponderance of butyrate-producing bacteria in the gut microbiome. investigators will use an inpatient sample in order to standardize meals, exercise and environmental mediators. this is considered a feasibility, pilot study in order to apply for future grant funding. investigators will recruit patients from the treatment research program inpatient unit, maryland psychiatric research center, university of maryland school of medicine.


Eligibility criteria:
inclusion criteria: 1. dsm-iv-tr /dsm 5 diagnosis of schizophrenia or schizoaffective disorder; 2. age 18-64 years; 3. currently hospitalized for at least 7 days 4. currently treated with an antipsychotic, with no dose changes in last 14 days 5. ability to participate in the informed consent process, as determined by a score of 10 or greater on the evaluation to sign consent exclusion criteria: 1. gastrointestinal disorders, including, but not limited to crohn's disease, irritable bowel syndrome, celiac disease, 2. organic brain disorder, including cerebrovascular accident; epilepsy; traumatic brain injury, loss of consciousness (loc) for more than 30 minutes 3. mental retardation 4. antibiotic or immune therapy within the last three months 5. prebiotic or probiotic treatment within the last three months 6. inability to understand english 7. inability to cooperate with study procedures 8. pregnant women 9. prisoner status 10. for mri only contraindication for mri scanning (e.g. metal in body, pacemaker).
efficacy and safety of sr58611a in patients with a generalized anxiety disorder

Conditions: Anxiety Disorder

Summary: to evaluate the efficacy of a fixed dose of sr58611a (350mg q12) compared to placebo in patients with generalizedanxiety disorder (gad) using escitalopram (10 mg qd) as positive control. to evaluate the tolerability and safety of sr58611a in patients with gad.

the current study will be conducted to evaluate the efficacy, safety, and tolerability of sr58611a (350 mg q12) compared to placebo in patients with generalized anxiety disorder (gad), using escitalopram (10 mg qd) as a positive control. this is an 8-week, double-blind, randomized, 3-parallel-group, placebo- and escitalopram-controlled, study.a 1-week, placebo, single-blind period precedes the 8-week randomized treatment period. a safety follow up visit (segment c) is scheduled 1 week after the acute treatmentperiod (segment b) or early termination. this trial is designed to compare the efficacy, safety, and tolerability of sr58611a to placebo. in this study, escitalopram, a selective serotonin reuptake inhibitor (ssri) antidepressant, is used as a positive control and has been chosen as the comparator agentas it is approved for treatment of gad at a dose of 10 mg once daily.

Eligibility criteria:
inclusion criteria: main inclusion criteria: 1. out-patients, 18 year and older. 2. generalized anxiety disorder (gad) according todsm-iv-tr criteria / mini. 3. minimum total score of 20 on the 14-item hamiltonanxiety rating scale (ham-a) exclusion criteria: main exclusion criteria: 1. patients with a diagnosis of major depressive disorder within 6 months of study entry. 2. patients with a montgomery-asberg depression rating scale (madrs) total score of 18 or higher 3. patients who are assessed to have a moderate to high current risk for suicide according to the mini, or at imminent risk for a suicide attempt 4. patients with other current anxiety disorder (within 6 months) assessed with the mini:- agoraphobia, social phobia,- panic disorder,- obsessive compulsive disorder,- post-traumatic stress disorder, acute stress disorder. 5. patients with a lifetime history according to the mini of:- bipolar disorders,- psychotic disorders,- antisocial personality disorder. 6. patients with a current history according to the mini of:- anorexia nervosa or bulimia nervosa in the past 6 months,- alcohol dependence or abuse or substance dependence or abuse in the past 12 months except nicotine or caffeine dependence. 7. patients who have received non-pharmacologic, somatic treatments for psychiatric disease 8. patients who have initiated, stopped, or changed the frequency or nature of psychotherapy within 3 months prior to screening.

Keywords: anxiety disorder